Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. - Wikidata - awgldk - TriplyDB

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

http://www.wikidata.org/entity/Q39633214

about

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB Recent developments in treatment of latent tuberculosis infection Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis Risk factors for treatment default in close contacts with latent tuberculous infection.Regimens of less than six months for treating tuberculosis.Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study Adverse reactions to first-line antituberculosis drugs.A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients.Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.Initiation and completion rates for latent tuberculosis infection treatment: a systematic review.Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review.Isoniazid Toxicity among an Older Veteran Population: A Retrospective Cohort Study.Antituberculosis drugs and hepatotoxicity.Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury.Review article: the diagnosis and management of Crohn's disease in populations with high-risk rates for tuberculosis.Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment.Anti-tuberculosis drug-induced hepatitis in renal transplant patient with pulmonary and extra pulmonary tuberculosis New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.An Update on Drug-induced Liver Injury.Treatment of latent tuberculosis infection: An update.Hepatotoxic effects of therapies for tuberculosis.Current management options for latent tuberculosis: a review.Latent tuberculosis: revised treatment guidelines.Predictors of positive tuberculin skin test (TST) results after 2-step TST among health care workers in Manitoba, Canada.Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers.Needed: new and better tools to combat latent tuberculosis infection.Tuberculosis prevention and control in long-term-care facilities for older adults.Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?Use of isoniazid for latent tuberculosis infection in a public health clinic.Tuberculosis chemotherapy: still a double-edged sword.

P2860

Q24201325-C4036CDF-59F3-43D5-8A05-7204BCF4A0BB Q24630473-F51743E7-386F-4FD8-8003-2F0CDC2FC35D Q24650581-461A08D5-69F0-4B5A-80DE-3A5C36575F42 Q28207601-8DBD7498-4155-4A09-A310-671F21C5E010 Q28537807-EAB7263C-803F-454F-9F48-CC9A8D4730D1 Q33768706-65985EB2-31EF-4CF1-AA2A-D73EBCF30716 Q33909202-9E112325-470E-4CEB-9E22-64BF864177B8 Q34116293-8EC57EF8-900E-4993-8367-47D6A1309B7F Q34312746-C9382B01-592B-4A53-9243-4338128C413B Q34497890-5F62944F-FC10-4ABC-A5FB-0048B05DEA3F Q34567560-2D6FED64-5AB2-4FF0-BB0D-2FC37D706D41 Q34660150-FC147310-6995-4449-9348-6809DC1C2746 Q35065871-F7834425-7CDD-44B3-90DB-826177AEA06B Q35537181-D6CD47C4-0D41-4CD0-BCBE-9A060C561F12 Q35779318-2FA98804-C01D-48D2-9B6C-2DC64246F8F0 Q35786010-D095392D-6B36-41B2-906C-3C38696BDDCC Q36019231-1F27D76A-4794-4B68-9079-85977983E6B1 Q36042709-8388F823-2583-4ABA-AF38-1F1DF1D22A84 Q36567400-6F9DC63F-7F81-4F9C-9A58-0076C438A585 Q36628708-65FAEC0E-A15A-4935-81A6-0A77D63B68A9 Q36725202-EC88DEA3-4114-450B-BFD9-359CEA28E97F Q36836019-341F2902-7CD9-49F1-86BF-8418AF361142 Q36998032-EF8101CC-5C26-43CE-9366-382137D66152 Q37043444-39ECA4C0-5417-46F8-A17A-BB04EDC5C2DF Q37099326-B5F37B18-AD40-474E-9E74-F37D9CCBAC2F Q37346929-86B36DC6-9629-4627-9B4B-03E2EBC84DD5 Q37373820-A8DCA011-0970-4CA5-ADFB-B990C2AAE01B Q37613520-5F57077C-9616-48E0-AD8D-F469CFCF3E54 Q37735306-0292B5A1-79F8-40B6-9ADC-84A181E1444A Q37784382-94A1EE42-089E-46C5-8568-954402628AC1 Q38066198-B8CAB4C1-B0E7-47F7-A6D6-A4830DBD6B39 Q39982606-89F6BC38-E7AF-4C4D-85C4-F90A8F0E103B Q40463610-5228DD1F-1F46-4925-84E5-EF7A78B508B0 Q41657767-B9394738-E771-496D-9B19-FB3444975FCC Q42618217-3A08E2CA-7CB4-4727-BCBC-A7841F12B716 Q42859871-F026DD2B-BF47-4A14-8BAD-2C4D5732B679 Q44157851-940144F2-C387-4F2D-BB31-F86798749FE8 Q44353708-2498A8C1-5240-46CC-92E2-8DEF4F83B3ED Q44440459-E827F99A-A2C4-46A0-9AB1-C19E0B9F7EC1 Q44456272-6886266C-FCA1-4A06-9E7C-0084B6871D4E

P2860

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

http://www.wikidata.org/entity/Q39633214

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Short-course rifampin and pyra ...... a multicenter clinical trial.

@en

Short-course rifampin and pyra ...... a multicenter clinical trial.

@nl

type

label

Short-course rifampin and pyra ...... a multicenter clinical trial.

@en

Short-course rifampin and pyra ...... a multicenter clinical trial.

@nl

prefLabel

Short-course rifampin and pyra ...... a multicenter clinical trial.

@en

Short-course rifampin and pyra ...... a multicenter clinical trial.

@nl

P1433

Q39633214-C831E10A-ED9B-42CB-99D3-586E71288C09

P1476

Q39633214-24593095-0669-4D55-BC57-E3429B9C4D35

P2093

Q39633214-1470DD83-F035-49AE-8AF9-7A6DAD5F6E39

Q39633214-23B648E3-9FC4-42E8-9368-578283B5197B

Q39633214-3202BB59-5A4D-4B16-BE8C-790857BA3B9B

Q39633214-3D185A62-770B-490C-8DCB-18667412B4AE

Q39633214-698B3599-A5B4-430E-99D9-6365BB107933

Q39633214-988543E3-6F1C-4CD8-9112-9452552A240B

Q39633214-D09FC235-A950-4971-8BCF-C696B08F8B43

Q39633214-D40462C0-248D-49C9-B992-EB2145F87BFC

Q39633214-EA3812BC-1808-40D7-A082-E22D547C897D

P304

Q39633214-2CB76755-7B63-45B2-9C1F-5ABED4E4DECA

P31

Q39633214-B1FA42DA-A9B9-44E1-ABC4-6BA3A47B2A7B

P356

Q39633214-65434945-16DE-44D3-8539-DF7213403986

P407

Q39633214-DEA4079A-4EF4-4890-83AC-104F7AFE2CDF

P433

Q39633214-80C72405-F557-4968-8A1F-7EDEED35E9AB

P478

Q39633214-BC35548C-E1CF-4331-BD74-DC68A14D29D4

P50

Q39633214-7AA2AF47-812D-4306-95EC-349D7ACD9C2B

P577

Q39633214-A8E97060-037D-4BB0-9672-09AB1AE4991E

P698

Q39633214-4836D4D9-93BD-401E-8905-4CCBA6CBB82B

P921

Q39633214-22160460-6360-44EE-80A8-B666000560A0

Q39633214-6E6ABE5D-BBA5-482F-831C-60FF21628A47

P356

0003-4819-137-8-200210150-00007

P1433

Annals of Internal Medicine

P1476

Short-course rifampin and pyra ...... : a multicenter clinical trial

@en

P2093

Charles L Daley

http://www.w3.org/2001/XMLSchema#string

Eric Vittinghoff

http://www.w3.org/2001/XMLSchema#string

Henry M Blumberg

http://www.w3.org/2001/XMLSchema#string

Jussi J Saukkonen

http://www.w3.org/2001/XMLSchema#string

L Masae Kawamura

http://www.w3.org/2001/XMLSchema#string

Mark D King

http://www.w3.org/2001/XMLSchema#string

Philip C Hopewell

http://www.w3.org/2001/XMLSchema#string

Robert M Jasmer

http://www.w3.org/2001/XMLSchema#string

Short-Course Rifampin and Pyra ...... n (SCRIPT) Study Investigators

http://www.w3.org/2001/XMLSchema#string

P304

640-647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-137-8-200210150-00007

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12379063

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

multicenter trial